Tuesday, November 02, 2021

Cumulative New Cases and Deaths

<table>
<thead>
<tr>
<th></th>
<th>Worldwide</th>
<th>ASEAN+3</th>
<th>Plus-3</th>
<th>ASEAN</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cases</strong></td>
<td>247,129,785</td>
<td>15,434,202</td>
<td>2,201,280</td>
<td>13,232,922</td>
</tr>
<tr>
<td><strong>Deaths</strong></td>
<td>5,005,638</td>
<td>305,155</td>
<td>26,005</td>
<td>279,150</td>
</tr>
</tbody>
</table>

Source: Haver Analytics, sourced from Johns Hopkins University; and AMRO staff calculations.

Recent Developments

**Global News**
- Globally, more than 5 million people have died from Covid-related complications.
- **Russia** has extended the paid non-working week until November 8 after weekly cases and deaths rose to all-time highs of 38,194 and 1,116, respectively, this week.
- **Schools in New Delhi** have reopened for physical classes with 50 percent capacity, after closing for almost 20 months. Attendance is voluntary and virtual classes will continue.

**Regional News**
- **Cambodia** has officially reopened its economy this week. Some regional airlines have announced the resumption of direct flights to Cambodia.
- **Lao PDR** has extended current mobility restrictions until November 14 as daily cases reached a record-high of more than 670 cases in the past week.
- **Korea** has eased containment restrictions after vaccinating more than 75 percent of its population. The use of vaccine passports has also been introduced at high-risk venues.
- **Indonesia** has issued an emergency use authorization for the inoculation of children aged six to 11 years old using the Sinovac vaccine.
- **Myanmar** has reopened all basic education schools, except those in high-risk areas, amid a decrease in daily infections in the country.

**Vaccine News**
- **Novavax** has received emergency use authorization in **Indonesia**, its first approval in the world. In **Indonesia**, the shot will be manufactured by the world’s largest vaccine manufacturer, Serum Institute of India, and sold under the brand name, Covovax.
- **Shionogi**, a **Japanese** pharmaceutical company, will begin Phase 3 clinical trial for its recombinant protein COVID-19 vaccine this month. The trials would be mainly conducted in **Vietnam** and other Asian countries.
ASEAN+3 and Selected Economies: COVID-19 Cases and Deaths

Source: Haver Analytics, sourced from Johns Hopkins University; and AMRO staff calculations.
1/ Values show the 7-day average.

ASEAN+3 and Selected Economies: Cumulative Vaccines Administered

Source: Haver Analytics, sourced from Our World in Data; and AMRO staff calculations.
1/ Single vaccination doses only. This does not measure the number of people vaccinated, as two doses are required with most available vaccines. Data is reported at irregular intervals; numbers show latest available.

ASEAN+3 and Selected Economies: Vaccinations and Aspired Population Coverage

Source: Our World in Data via Haver Analytics; various media sources; Economist Intelligence Unit; and AMRO staff estimates and calculations.

Note: Percent of population vaccinated shows total administered doses divided by two to reflect the two-dose regime of most vaccines—it does not necessarily reflect the actual number of fully vaccinated people. Aspired 2021 targets and completion dates of widespread vaccination are goals, forecasts, or estimates.

---

**Economy** | **Total Cases ('000)** | **Cases per 1M Population** | **New Cases**<sup>1</sup> | **New Cases per 1M Pop.**<sup>1</sup> | **Total Deaths**<sup>1</sup> | **Fatality Rate (%)**
---|---|---|---|---|---|---
Global | 247,130 | 433,117 | 12,493 | 0.2 | 5,008,638 | 7,151 | 2.0
ASEAN+3 | 15,434 | 32,214 | 797 | 0.2 | 305,155 | 476 | 2.0
Plus-3 | 2,201 | 2,844 | 1,095 | 0.1 | 26,005 | 22 | 1.2
ASEAN | 13,233 | 29,370 | -299 | 0.2 | 279,150 | 454 | 2.1

**Economy** | **Total Cases ('000)** | **Cases per 1M Population** | **New Cases**<sup>1</sup> | **New Cases per 1M Pop.**<sup>1</sup> | **Total Deaths**<sup>1</sup> | **Fatality Rate (%)**
---|---|---|---|---|---|---
China | 97 | 69 | 0 | 0 | 4,636 | 0 | 4.8
Hong Kong, China | 12 | 1,617 | 0 | -1 | 213 | 0 | 1.7
Japan | 1,724 | 13,706 | 828 | 7 | 18,714 | 22 | 2.2
Korea | 368 | 7,069 | 5681 | 17 | 28,975 | 10 | 0.8

**Economy** | **Total Cases ('000)** | **Cases per 1M Population** | **New Cases**<sup>1</sup> | **New Cases per 1M Pop.**<sup>1</sup> | **Total Deaths**<sup>1</sup> | **Fatality Rate (%)**
---|---|---|---|---|---|---
Indonesia | 4,245 | 15,729 | 2 | -116 | 143,423 | 27 | 3.4
Malaysia | 2,476 | 74,593 | 171 | -87 | 28,975 | 69 | 1.2
Philippines | 2,790 | 25,356 | 38 | -708 | 43,276 | 191 | 1.6
Singapore | 201 | 35,223 | 627 | -9 | 421 | 13 | 0.2
Thailand | 1,920 | 28,231 | 128 | -616 | 19,260 | 66 | 1.0

**Economy** | **Total Cases ('000)** | **Cases per 1M Population** | **New Cases**<sup>1</sup> | **New Cases per 1M Pop.**<sup>1</sup> | **Total Deaths**<sup>1</sup> | **Fatality Rate (%)**
---|---|---|---|---|---|---
Brunel Darussalam | 13,25 | 29,370 | 273 | -68 | 89 | 1 | 0.7
Cambodia | 118.61 | 7,069 | 6 | -43 | 2,794 | 7 | 2.4
Lao PDR | 44.96 | 5,637 | 90 | 111 | 67 | 2 | 0.2
Myanmar | 500.95 | 9,385 | 16 | -18 | 18,714 | 22 | 3.7
Vietnam | 926.72 | 9,613 | 51 | 1,255 | 22,131 | 56 | 2.4

**Economy** | **Total Cases ('000)** | **Cases per 1M Population** | **New Cases**<sup>1</sup> | **New Cases per 1M Pop.**<sup>1</sup> | **Total Deaths**<sup>1</sup> | **Fatality Rate (%)**
---|---|---|---|---|---|---
Australia | 173 | 6,667 | 61 | -509 | 1,756 | 15 | 1.0
Brazil | 21,815 | 103,203 | 53 | -645 | 607,922 | 303 | 2.8
France | 6,990 | 107,553 | 88 | 685 | 115,296 | 20 | 1.6
Germany | 4,619 | 55,669 | 230 | 5,283 | 99,854 | 16 | 1.1
India | 34,286 | 25,356 | 9 | -3,460 | 458,437 | 481 | 1.3
United Kingdom | 9,140 | 135,907 | 702 | 2,680 | 141,098 | 218 | 1.5
United States | 45,881 | 138,591 | 225 | 782 | 743,473 | 1,384 | 1.6

Source: Haver Analytics, sourced from Our World in Data; and AMRO staff calculations.
1/ Values show the 7-day average.